Dr Federico Piñero specialises in internal medicine, hepatology and liver transplantation. He currently works at the Hospital Universitario Austral, Buenos Aires. Argentina. From 2008 to 2009 he participated in basic research on colorectal cancer immunology. Dr Piñero’s current clinical research focuses on hepatocellular carcinoma (HCC). He obtained a Masters Science in Clinical Epidemiology and Research for Public Health from the University of Buenos Aires (MSCE) and is now finishing his PhD on liver transplantation and HCC in Latin America. Dr Piñero has presented his clinical research at various national and international liver meetingm and he has won several national and international awards. He also won two national grants from the Argentine Institute of Cancer focusing on microbiome and liver cancer (ongoing cohort study evaluating dynamic changes of gut microbiome as a risk factor of HCC development). He is part of the Editorial Board and has reviewed different research from several indexed Journals. He is a regional coordinator of HCC in ALEH (Latin American Association for the Study of Liver Diseases). Relevant publications Piñero F, Marciano S, Villamil A, et al. Sicker patients for liver transplantation: Meld, Meld sodium, and integrated Meld’s prognostic accuracy in the assessment of post transplantation events at a single center from Argentina. J Transplantation 2013; Article ID 102590. Piñero F, Campaña AG, Mendizabal M, et al. Domino liver graft with hepatocellular carcinoma used as bridge therapy for a patient with acute liver failure: a case report. Liver Transpl 2014; vol 20 (3):386-87. Piñero F, Mendizabal M, Casciato P, et al. Is recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? towards a predictive recurrence score. Ann Hepatol 2014; vol 13 (2): 211-18. Piñero F, Mendizabal M, Quiros R, et al. Neurological events after liver transplantation: a single-center experience. Transpl Int 2014; 27 (2): 1244 -52. Piñero F, Marciano S, Gadano AC. A Case of Granulomatous Hepatitis and Pancytopenia Secondary to Bacillus Chalmette Guerin Immunotherapy (BCG). Medicinal Chemistry 2014, vol 4 (7): 531-532. Piñero F, Bandi J, Tisi Baña M, et al. Early predictors of renal dysfunction in cirrhotic patients after liver transplantation. Acta Gastroenterol Latinoam 2014; 44: 284-87. Piñero F, Marciano S, Anders M, et al. Screening for liver cancer during transplant waiting list: a multicenter study from South America. Eur J Gastroenterol Hepatol 2015; 27 (3): 355-60. Piñero F, Fauda M, Quiros R et al. Predicting early discharge from hospital after liver transplantation (ERDALT) at a single center: a new model. Ann Hepatol 2015; 6(14):845-855. Piñero F, Marciano S, Anders M, et al. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2016; 28 (4): 421-427. Piñero F, Marciano S, Anders M, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: a South American experience. Acta Gastroenterológica Latinoamericana (Epub). Piñero F, Tisi Baña M, de Ataide EC, et al. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016; 36:1657-1667. EDITORIAL comment: C Toso, et al. Liv Int 2016; 36:1580-81. Piñero F, Carrihlo FJ, Silva MO. Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need. Liver Int 2017 May;37(5):648-650. doi: 10.1111/liv.13417. Piñero F, Costa P, Boteon YL, et al. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Annals Hepatol 2018, 17(2):256-267. Piñero F, Marciano S, Fernandez N, et al. Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018, 30(4):376-383. Piñero F and Silva M. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl 2017, vol 23, issue 12: 1628-1629. doi: 10.1002/lt.24962. Piñero F, Pages J, Marciano S, et al. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018, vol 10, issue 1: 41-50. doi: 10.4254/wjh.v10.i1.41 Piñero F, Cheang Y, Mendizabal M, et al. Incidence, risk factors, and outcomes related with neurological events after liver transplantation in adult and pediatric recipients. Pediatr Transplant 2018, 2(3):e13159. doi: 10.1111/petr.13159. Piñero F, Costa P, Boteon YL, et al. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clin Res Hepatol Gastroenterol 2018; 42 (5):443-452. Piñero F, Poniachik J, Ridruejo E, et al. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. World J Gastroenterol 2018; October 7;24 (37):4224-4229. Piñero F, et al. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Annals Hepatol 2018; Epub ahead of print. Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. World J Gastroenterol 2018; October 7;24 (37):4224-4229. Piñero F, Rubinstein F, Silva M, et al. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness? Dig Dis Sci. 2019 Mar;64(3):718-728 Piñero F, Mendizabal M, Ridruejo E, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019, Epub ahead of print. Malvicini M, Rizzo M, Alaniz L, Piñero F, et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res 2009 Dec 1;15(23):7256-65.
Bayer, Roche, Raffo and LKM.